Physician profile
Doria L Devare
NPI 1295731230
$2,491.29
in general payments reported to CMS, 2019-2025
16 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $110 · 2021: $356 · 2022: $693 · 2023: $97.48 · 2024: $339 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.25 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.15 | 2019-2022 | |
| Amgen INC. | $328.08 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $308.09 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $156.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $124.01 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $112.50 | 2022 | |
| Pfizer INC. | $109.87 | 2020 | |
| Ucb, INC. | $104.86 | 2025 | Nayzilam |
| Allergan, INC. | $102.54 | 2019 | |
| Inspire Medical Systems, INC. | $97.48 | 2023 | Inspire |
| Axsome Therapeutics, INC. | $82.90 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $81.00 | 2022 | |
| Metuchen Pharmaceuticals | $15.80 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doria Devare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.